Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://www.ncbi.nlm.nih.gov/pubmed/29106740
http://dx.doi.org/10.1002/jcph.1025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://www.ncbi.nlm.nih.gov/pubmed/29106740
http://dx.doi.org/10.1002/jcph.1025

Ejemplares similares